Dominik Escher is a founding partner of Pureos Bioventures. He is also a co-founder and Executive Chairman of CDR-Life. Previously, he was a founder and CEO of ESBATech, which was acquired in 2009 by Alcon (Novartis) for USD 589 million. As a biotech entrepreneur, he raised USD 90 million for ESBATech to develop novel antibody fragments from discovery to clinical proof-of-concept, delivering multiple clinically successful products (e.g. Beovu). Dominik obtained his Ph.D. in Molecular Biology from the University of Zurich and also holds a Masters Degree in Education with specialization in Management and Organization from the ETH of Zurich.